Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Reviewer: Eric Shinohara MD, MSCI
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 4 de junio del 2008
Presenter: Allegra, C.J.
Presenter's Affiliation: University of Florida
Type of Session: Scientific
Materials and Methods
OX ≥10 of 12 cycles
5-FU ≥10 of 12 cycles
Bev ≥21 of 26 cycles
· Median follow up was 28.5 months for both arms, median age was ~58 yo for both arms and ~50% of patients were male for both arms.
· Significantly more patients received 1000 mg of OX cumulatively in group B compared with group A.
· The median cumulative OX dose delivered was 850 mg for group A and 880 mg for group B (p=0.002).
· The median duration that patients in group B took Bev was 11.6 months. The rate at which patients stopped Bev treatment appeared to correlate with when patients dropped out of chemotherapy. After chemotherapy ended, Bev drop out continued but at a slower rate.
o 70% of patients in group A versus 77% of patients in group B had grade 3 or higher toxicity, which was significantly different.
o There was no difference in venous thrombosis, neutropenia or fatigue between the two groups.
o The frequency of neuropathy was similar between the two arms, but there was more grade 3 of higher neuropathy in group B, likely due to the higher OX dose.
o There was no difference in the rates of cardiac, CNS, GI perforation or hemorrhage between the two groups.
o There was a decrease in thrombocytopenia and allergic reaction in group B.
o There were higher rates of hypertension, pain, proteinuria, and wound complications in group B.
§ 23 (1.7%) of patients had serious wound complications, all were grade 3
§ 22 required additional surgery
§ ½ stopped Bev
§ Median time to the event was 5 months
§ Pain was predominantly in the chest, joints and muscles
§ After the completion of chemotherapy, patients still had wound complications, hypertension, proteinuria, and pain, implying that these toxicities were due to the Bev.
o In both arms, older patients tolerated the treatment worse, with patients older than 60 having more grade 3 and 4 toxicity.
Endocrine System Cancers
Head and Neck Cancers
Urinary Tract Cancers
Bone Marrow Transplants
General Treatment Concerns
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
Cancer Resource List
Resources for Young Adults